Transgenic expression of inclusion body myopathy associated mutant p97/VCP causes weakness and ubiquitinated protein inclusions in mice

Human Molecular Genetics

Volumn 16, Issue 8, 2007, Pages 919-928

  Weihl, Conrad C ^a   Miller, Sara E ^a   Hanson, Phyllis I ^a   Pestronk, Alan ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN 3; COMPLEMENTARY DNA; EVANS BLUE; MUTANT PROTEIN; PROTEASOME; PROTEIN P97; UBIQUITIN; VALOSIN CONTAINING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CELL VACUOLE; CONTROLLED STUDY; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; INCLUSION BODY MYOPATHY; MEMBRANE STRUCTURE; MOUSE; MUSCLE CELL; MUSCLE WEAKNESS; MUTATIONAL ANALYSIS; MYOPATHY; NEUROPATHOLOGY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SARCOLEMMA; SKELETAL MUSCLE; TISSUE SPECIFICITY; TRANSGENIC MOUSE; UBIQUITINATION;

ADENOSINE TRIPHOSPHATASES; ANIMALS; CELL CYCLE PROTEINS; GENE EXPRESSION; INCLUSION BODIES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUSCLE WEAKNESS; MUSCLE, SKELETAL; MUTANT PROTEINS; MYOSITIS, INCLUSION BODY; ORGAN SPECIFICITY; PROTEASOME ENDOPEPTIDASE COMPLEX; SARCOLEMMA; UBIQUITIN;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 34447093377     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddm037     Document Type: Article

References (31)

1. Askanas, V. and Engel, W.K. (2005) Molecular pathology and pathogenesis of inclusion-body myositis. Microsc. Res. Tech., 67, 114-120.
2. Watts, G.D., Wymer, J., Kovach, M.J., Mehta, S.G., Mumm, S., Darvish, D. Pestronk, A., Whyte, M.P. and Kimonis, V.E. (2004) Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat. Genet. 36, 377-381.
3. Kimonis, V.E. and Watts, G.D. (2005) Autosomal dominant inclusion body myopathy, Paget disease of bone, and frontotemporal dementia. Alzheimer Dis. Assoc. Disord., 19 (Suppl. 1), S44-S47.
4. Hubbers, C.U., Clemen, C.S., Kesper, K., Boddrich, A., Hofmann, A., Kamarainen, O., Tolksdorf, K., Stumpf, M., Reichelt J., Roth, U. et al. (2006) Pathological consequences of VCP mutations on human striated muscle. Brain, 130, 381-393.
5. Kovach, M.J., Waggoner, B., Leal, S.M., Gelber, D., Khardori, R., Levenstien, M.A., Shanks, C.A., Gregg, G., Al-Lozi, M.T., Miller, T. et al. (2001) Clinical delineation and localization to chromosome 9p13.3-p12 of a unique dominant disorder in four families: Hereditary inclusion body myopathy, Paget disease of bone, and frontotemporal dementia. Mol. Genet. Metab., 74, 458-475.
6. Forman, M.S., Mackenzie, I.R., Cairns, N.J., Swanson, E., Boyer, P.J., Drachman. D.A., Jhaveri, B.S., Karlawish, J.H., Pestronk, A., Smith, T.W. et al. (2006) Novel ubiquitin neuropathology in frontotemporal dementia with valosin-containing protein gene mutations. J. Neuropathol. Exp. Neurol., 65, 571-581.
7. Schroder, R., Watts, G.D., Mehta, S.G., Evert, B.O., Broich, P., Fliessbach, K., Pauls, K., Hans, V.H., Kimonis, V. and Thal, D.R. (2005) Mutant valosin-containing protein causes a novel type of frontotemporal dementia. Ann. Neurol., 57, 457-461.
8. Fratta, P., Engel, W.K., McFerrin, J., Davies, K.J., Lin, S.W. and Askanas, V. (2005) Proteasome inhibition and aggresome formation in sporadic inclusion-body myositis and in amyloid-beta precursor protein-overexpressing cultured human muscle fibers. Am. J. Pathol. 167, 517-526.
9. Vattemi, G., Engel, W.K., McFerrin, J. and Askanas, V. (2004) Endoplasmic reticulum stress and unfolded protein response in inclusion body myositis muscle. Am. J. Pathol., 164, 1-7.
10. Wang, Q., Song, C. and Li, C.C. (2004) Molecular perspectives on p97-VCP: Progress in understanding its structure and diverse biological functions. J. Struct. Biol., 146, 44-57.
11. Dai, R.M. and Li, C.C. (2001) Valosin-containing protein is a multi-ubiquitin chain-targeting factor required in ubiquitin-proteasome degradation. Nat. Cell Biol., 3, 740-744.
12. Hatakeyama, S., Matsumoto, M., Yada, M. and Nakayama, K.I. (2004) Interaction of U-box-type ubiquitin-protein ligases (E3s) with molecular chaperones. Genes Cells, 9, 533-548.
13. Zhong, X., Shen, Y., Ballar, P., Apostolou, A., Agami, R. and Fang, S. (2004) AAA ATPase p97/valosin-containing protein interacts with gp78, a ubiquitin ligase for endoplasmic reticulum-associated degradation. J. Biol. Chem., 279, 45676-45684.
14. Rabinovich, E., Kerem, A., Frohlich, K.U., Diamant, N. and Bar-Nun, S. (2002) AAA-ATPase p97/Cdc48p, a cytosolic chaperone required for endoplasmic reticulum-associated protein degradation. Mol. Cell. Biol., 22, 626-634.
15. Dalal, S., Rosser, M.F., Cyr, D.M. and Hanson, P.I. (2004) Distinct roles for the AAA ATPases NSF and p97 in the secretory pathway. Mol. Biol. Cell, 15, 637-648.
16. Weihl, C.C., Dalal, S., Pestronk, A. and Hanson, P.I. (2006) Inclusion body myopathy-associated mutations in p97/VCP impair endoplasmic reticulum-associated degradation. Hum. Mol. Genet., 15, 189-199.
17. Shield, M.A., Haugen, H.S., Clegg, C.H. and Hauschka, S.D. (1996) E-box sites and a proximal regulatory region of the muscle creatine kinase gene differentially regulate expression in diverse skeletal muscles and cardiac muscle of transgenic, mice. Mol. Cell Biol., 16, 5058-5068.
18. Sugarman, M.C., Yamasaki, T.R., Oddo, S., Echegoyen, J.C., Murphy, M.P., Golde, T.E., Jannatipour, M., Leissring, M.A. and LaFerla, F.M. (2002) Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle. Proc. Natl. Acad. Sci. USA, 99, 6334-6339.
19. Guyant-Marechal, L., Laquerriere, A., Duyckaerts, C., Dumanchin, C., Bou, J., Dugny, F., Le Ber, I., Frebourg, T., Hannequin, D. and Campion, D. (2006) Valosin-containing protein gene mutations: Clinical and neuropathologic features. Neurology, 67, 644-651.
20. Connolly, A.M., Keeling, R.M., Mehta, S., Pestronk, A. and Sanes, J.R. (2001) Three mouse models of muscular dystrophy: The natural history of strength and fatigue in dystrophin-, dystrophin/utraphin-, and laminin alpha2-deficient mice. Neuromuscul. Disord., 11, 703-712.
21. Matsuda, R., Nishikawa, A. and Tanaka, H. (1995) Visualization of dystrophic muscle fibers in mdx mouse by vital stainin with Evans blue: evidence of apoptosis in dystrophin-deficient muscle. J. Biochem. (Tokyo), 118, 959-964.
22. Straub, V., Rafael, J.A., Chamberlain, J.S. and Campbell, K.P. (1997) Animal models for muscular dystrophy show different patterns of sarcolemmal disruption. J. Cell Biol., 139, 375-385.
23. Chevessier, F., Marty, I., Paturneau-Jouas, M., Hantai, D. and Verdiere-Sahuque, M. (2004) Tubular aggregates are from whole sarcoplasmic reticulum origin: Alterations in calcium binding protein expression in mouse skeletal muscle during aging. Neuromuscul. Disord., 14, 208-216.
24. Askanas, V. and Engel, W.K. (2002) Inclusion-body myositis and myopathies: Different etiologies, possibly similar pathogenic mechanisms. Curr. Opin. Neurol., 15, 525-531.
25. Frosk, P., Weiler, T., Nylen, E., Sudha, T., Greenberg, C.R., Morgan, K., Fujiwara, T.M. and Wrogemann, K. (2002) Limb-girdle muscular dystrophy type 2H associated with mutation in TRIM32, a putative E3-ubiquitin-ligase gene. Am. J. Hum. Genet., 70, 663-672.
26. Zhao, L., Longo-Guess, C., Harris, B.S., Lee, JW. and Ackerman, S.L. (2005) Protein accumulation and neurodegeneration in the woozy mutant mouse is caused by disruption of SIL 1, a cochaperone of BiP. Nat. Genet., 37, 974-979.
27. Moussa, C.E., Fu, Q., Kumar, P., Shtifman, A., Lopez, J.R., Allen, P.D., LaFerla, F., Weinberg, D., Magrane, J., Aprahamian, T. et al. (2006) Transgenic expression of beta-APP in fast-twitch skeletal muscle leads to calcium dyshomeostasis and IBM-like pathology. FASEB J., 20, 2165-2167.
28. Woodman, S.E., Sotgia, F., Galbiati, F., Minetti, C. and Lisanti, M.P. (2004) Caveolinopathies: Mutations in caveolin-3 cause four distinct autosomal dominant muscle diseases. Neurology, 62, 538-543.
29. Galbiati, F., Volonte, D., Minetti, C., Bregman, D.B. and Lisanti, M.P. (2000) Limb-girdle muscular dystrophy (LGMD-1C) mutants of caveolin-3 undergo ubiquitination and proteasomal degradation: Treatment with proteasomal inhibitors blocks the dominant negative effect of LGMD-1C mutanta and rescues wild-type caveolin-3. J. Biol. Chem., 275 37702-37711.
30. Askanas, V., Engel, W.K. and Alvarez, R.B. (1993).Enhanced detection of congo-red-positive amyloid deposits in muscle fibers of inclusion body myositis and brain of Alzheimer's disease using fluorescence technique. Neurology, 43, 1265-1267.
31. Davies, J.E., Wang, L., Garcia-Oroz, L., Cook, L.J., Vacher, C., O'Donovan, D.G. and Rubinsztein, D.C. (2005) Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice. Nat. Med., 11, 672-677.